Mechanisms of drug resistance in kinases

Abstract

Introduction: Because of their important roles in disease and excellent ‘druggability’, kinases have become the second largest drug target family. The great success of the BCR-ABL inhibitor imatinib in treating chronic myelogenous leukemia illustrates the high potential of kinase inhibitor (KI) therapeutics, but also unveils a major limitation: the development of drug resistance. This is a significant concern as KIs reach large patient populations for an expanding array of indications.

Areas covered: We provide an up-to-date understanding of the mechanisms through which KIs function and through which cells can become KI-resistant. We review current and future approaches to overcome KI resistance, focusing on currently approved KIs and KIs in clinical trials. We then discuss approaches to improve KI efficacy and overcome drug resistance and novel approaches to develop less drug resistance-prone KI therapeutics.

Expert opinion: Although drug resistance is a concern for current KI therapeutics, recent progress in our understanding of the underlying mechanisms and promising technological advances may overcome this limitation and provide powerful new therapeutics.

Keywords::

• ABL
• Bcr
• CML
• drug resistance
• imatinib
• kinase

Acknowledgements

This is manuscript no. 20919 from The Scripps Research Institute. We apologize to our colleagues for citing reviews in lieu of several important original references due to limitations to the number of references allowed.

Notes

This box summarizes key points contained in the article.